1
|
Thornton RB, Kirkham LAS, Corscadden KJ, Coates HL, Vijayasekaran S, Hillwood J, Toster S, Edminston P, Zhang G, Keil A, Richmond PC. No evidence for impaired humoral immunity to pneumococcal proteins in Australian Aboriginal children with otitis media. Int J Pediatr Otorhinolaryngol 2017; 92:119-125. [PMID: 28012512 DOI: 10.1016/j.ijporl.2016.11.019] [Citation(s) in RCA: 7] [Impact Index Per Article: 1.0] [Reference Citation Analysis] [Abstract] [Key Words] [Track Full Text] [Journal Information] [Submit a Manuscript] [Subscribe] [Scholar Register] [Received: 08/23/2016] [Revised: 11/18/2016] [Accepted: 11/19/2016] [Indexed: 01/23/2023]
Abstract
BACKGROUND The Australian Aboriginal population experiences disproportionately high rates of otitis media (OM). Streptococcus pneumoniae is one of the main pathogens responsible for OM and currently no vaccine offering cross strain protection exists. Vaccines consisting of conserved antigens to S. pneumoniae may reduce the burden of OM in high-risk populations; however no data exists examining naturally acquired antibody in Aboriginal children with OM. METHODS Serum and salivary IgA and IgG were measured against the S. pneumoniae antigens PspA1 and 2, CbpA and Ply in a cross sectional study of 183 children, including 36 non-Aboriginal healthy control children and 70 Aboriginal children and 77 non-Aboriginal children undergoing surgery for OM using a multiplex bead assay. RESULTS Significant differences were observed between the 3 groups for serum anti-PspA1 IgA, anti-CbpA and anti-Ply IgG and for all salivary antibodies assessed. Aboriginal children with a history of OM had significantly higher antibody titres than non-Aboriginal healthy children with no history of OM and non-Aboriginal children with a history of OM for several proteins in serum and saliva. Non-Aboriginal children with a history of OM had significantly higher salivary anti-PspA1 IgG than healthy children, while all other titres were comparable between the groups. CONCLUSIONS Conserved vaccine candidate proteins from S. pneumoniae induce serum and salivary antibody responses in Aboriginal and non-Aboriginal children with a history of OM. Aboriginal children do not have an impaired antibody response to the antigens measured from S. pneumoniae and they may represent vaccine candidates in Indigenous populations.
Collapse
Affiliation(s)
- Ruth B Thornton
- School of Paediatrics and Child Health, The University of Western Australia, GPO Box D184, Perth, Western Australia, 6840, Australia; Telethon Kids Institute, The University of Western Australia, 100 Roberts Road, Subiaco, Western Australia, 6008, Australia.
| | - Lea-Ann S Kirkham
- School of Paediatrics and Child Health, The University of Western Australia, GPO Box D184, Perth, Western Australia, 6840, Australia; Telethon Kids Institute, The University of Western Australia, 100 Roberts Road, Subiaco, Western Australia, 6008, Australia.
| | - Karli J Corscadden
- School of Paediatrics and Child Health, The University of Western Australia, GPO Box D184, Perth, Western Australia, 6840, Australia; Telethon Kids Institute, The University of Western Australia, 100 Roberts Road, Subiaco, Western Australia, 6008, Australia.
| | - Harvey L Coates
- School of Paediatrics and Child Health, The University of Western Australia, GPO Box D184, Perth, Western Australia, 6840, Australia; Telethon Kids Institute, The University of Western Australia, 100 Roberts Road, Subiaco, Western Australia, 6008, Australia; Department of Otorhinolaryngology, Princess Margaret Hospital for Children, Roberts Road, Subiaco, Western Australia, 6008, Australia.
| | - Shyan Vijayasekaran
- School of Paediatrics and Child Health, The University of Western Australia, GPO Box D184, Perth, Western Australia, 6840, Australia; Telethon Kids Institute, The University of Western Australia, 100 Roberts Road, Subiaco, Western Australia, 6008, Australia; Department of Otorhinolaryngology, Princess Margaret Hospital for Children, Roberts Road, Subiaco, Western Australia, 6008, Australia.
| | - Jessica Hillwood
- School of Paediatrics and Child Health, The University of Western Australia, GPO Box D184, Perth, Western Australia, 6840, Australia.
| | - Sophie Toster
- School of Paediatrics and Child Health, The University of Western Australia, GPO Box D184, Perth, Western Australia, 6840, Australia.
| | - Phillipa Edminston
- School of Paediatrics and Child Health, The University of Western Australia, GPO Box D184, Perth, Western Australia, 6840, Australia.
| | - Guicheng Zhang
- School of Paediatrics and Child Health, The University of Western Australia, GPO Box D184, Perth, Western Australia, 6840, Australia; School of Public Health, Curtin University, GPO Box U1987, Perth, Western Australia, 6845, Australia.
| | - Anthony Keil
- PathWest Laboratory Medicine WA, Princess Margaret Hospital for Children, Roberts Road, Subiaco, Western Australia, 6008, Australia.
| | - Peter C Richmond
- School of Paediatrics and Child Health, The University of Western Australia, GPO Box D184, Perth, Western Australia, 6840, Australia; Telethon Kids Institute, The University of Western Australia, 100 Roberts Road, Subiaco, Western Australia, 6008, Australia; Department of Otorhinolaryngology, Princess Margaret Hospital for Children, Roberts Road, Subiaco, Western Australia, 6008, Australia.
| |
Collapse
|
2
|
Bogaert D, Veenhoven RH, Ramdin R, Luijendijk IHT, Rijkers GT, Sanders EAM, de Groot R, Hermans PWM. Pneumococcal conjugate vaccination does not induce a persisting mucosal IgA response in children with recurrent acute otitis media. Vaccine 2005; 23:2607-13. [PMID: 15780443 DOI: 10.1016/j.vaccine.2004.11.033] [Citation(s) in RCA: 6] [Impact Index Per Article: 0.3] [Reference Citation Analysis] [Abstract] [MESH Headings] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 05/19/2004] [Revised: 08/23/2004] [Accepted: 11/09/2004] [Indexed: 11/26/2022]
Abstract
AIM In a prospective controlled study in young children with a history of recurrent acute otitis media, we analyzed the salivary IgA and IgG antibody titers upon vaccination with a 7-valent pneumococcal conjugate vaccine (PCV) given once or twice, followed by a 23-valent polysaccharide booster vaccination. METHODS Salivary IgA and IgG antibody concentrations to vaccine serotype 6B, 14, 18C and 19F were measured by enzyme immunoassay in 38 samples of children vaccinated with PCV and 45 control samples. In the PCV group, 12 samples were taken prior to vaccination, 12 samples 4 weeks after the polysaccharide booster (8 months after the first conjugate vaccination) and 14 samples 7 months after the last vaccination (14 months after the first conjugate vaccination). In the control group 15 children were sampled at each of these three time points. RESULTS We observed an increase in salivary IgG antibody concentrations against serotype 6B, 14, and 18C 14 months after the primary vaccination in children vaccinated with PCV twice, although this was significant for serotype 14 only. There was no increase in salivary IgG antibody in children vaccinate with PCV once nor in control children. IgA antibody titers increased significantly after 8 and after 14 months in both the pneumococcal vaccine recipients and the controls. However, the observed increase in mean antibody titers was significantly higher in control children compared to the PCV group. CONCLUSION We suggest that repeated pneumococcal conjugate vaccination is necessary to induce an increase in salivary IgG antibodies and effectuate clearance of S. pneumoniae from the nasopharyngeal mucosa of children with recurrent acute otitis media. We hypothesize that the increase in salivary IgA is caused by the local boosting of the mucosal immune response by carriage and recurrent infections, which occurs less often in the PCV group compared to the control children.
Collapse
Affiliation(s)
- D Bogaert
- Laboratory of Pediatrics, Department of Pediatrics, University Medical Center Rotterdam, Erasmus MC-Sophia Rotterdam, Room Ee 1500, Dr. Molewaterplein 50, 3015 GE Rotterdam, The Netherlands
| | | | | | | | | | | | | | | |
Collapse
|
3
|
Zhang Q, Finn A. Mucosal immunology of vaccines against pathogenic nasopharyngeal bacteria. J Clin Pathol 2004; 57:1015-21. [PMID: 15452151 PMCID: PMC1770445 DOI: 10.1136/jcp.2004.016253] [Citation(s) in RCA: 27] [Impact Index Per Article: 1.4] [Reference Citation Analysis] [Abstract] [Key Words] [MESH Headings] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Accepted: 05/01/2004] [Indexed: 11/04/2022]
Abstract
The introduction of Haemophilus influenzae type b conjugate vaccines during the 1990s was followed by dramatic decreases both in the incidence of Haemophilus influenzae type b related invasive disease and in nasopharyngeal carriage of the organism. The extent of this effect has been influenced by the fact that Haemophilus influenzae type b conjugate vaccines reduce nasopharyngeal carriage and induce herd immunity. Based on the success of Haemophilus influenzae type b conjugate vaccines, chemical conjugation has been applied to the development of pneumococcal and meningococcal polysaccharide conjugate vaccines. Evidence has begun to accumulate that these new polysaccharide based conjugate vaccines can also reduce nasopharyngeal carriage and can induce immune responses at the local mucosal level, which may be responsible for these effects. This article reviews recent studies on mucosal immune responses induced by polysaccharide based vaccines and some protein vaccine antigens against several pathogenic nasopharyngeal bacteria, and discusses the mechanisms and functions of these immune responses that may help our understanding of mucosal immune responses to both immunisation and infection.
Collapse
Affiliation(s)
- Q Zhang
- Department of Clinical Sciences South Bristol, Institute of Child Health, University of Bristol, UBHT Education Centre, Upper Maudlin Street, Bristol BS2 8AE, UK
| | | |
Collapse
|
4
|
Weiser JN, Bae D, Fasching C, Scamurra RW, Ratner AJ, Janoff EN. Antibody-enhanced pneumococcal adherence requires IgA1 protease. Proc Natl Acad Sci U S A 2003; 100:4215-20. [PMID: 12642661 PMCID: PMC153073 DOI: 10.1073/pnas.0637469100] [Citation(s) in RCA: 123] [Impact Index Per Article: 5.9] [Reference Citation Analysis] [Abstract] [MESH Headings] [Grants] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/18/2022] Open
Abstract
IgA, the major class of Ig in secretions, classically functions by interfering with microbial attachment to host tissues. Many mucosal pathogens, including Streptococcus pneumoniae, express an IgA1 protease that may circumvent the protective effects of this Ig subclass. Because these proteases are specific for human IgA1, we generated human mAbs to the major surface antigen of the pneumococcus, its capsular polysaccharide, and tested their effect in a colonization model of bacterial adherence to respiratory epithelial cells in culture. Rather than inhibiting adherence, type-specific IgA1 markedly enhanced bacterial attachment to host cells, but only when cleaved by IgA1 protease. Neither antibodies of protease-insensitive subclasses (IgA2 and IgG) nor those directed against heterologous capsules had such activity. The adherence-promoting properties of cleaved antibodies correlated with the cationic characteristics of their variable segments, suggesting that bound Fab fragments may neutralize the inhibitory effect of negatively charged capsules on adhesive interaction with host cells. Coating of pneumococci with anticapsular polysaccharide antibody unmasked the bacterial phosphorylcholine ligand, allowing for increased adherence mediated by binding to the platelet activating factor receptor on epithelial cells. In addition, our findings provide evidence for a novel function of bacterial IgA1 proteases. These enzymes may enable pathogens to subvert the antigen specificity of the humoral immune response to facilitate adhesive interactions and persistence on the mucosal surface.
Collapse
Affiliation(s)
- Jeffrey N Weiser
- Department of Microbiology, University of Pennsylvania School of Medicine, Philadelphia, PA 19104, USA.
| | | | | | | | | | | |
Collapse
|
5
|
Syrogiannopoulos GA, Katopodis GD, Grivea IN, Beratis NG. Antimicrobial use and serotype distribution of nasopharyngeal Streptococcus pneumoniae isolates recovered from Greek children younger than 2 years old. Clin Infect Dis 2002; 35:1174-82. [PMID: 12410477 DOI: 10.1086/343824] [Citation(s) in RCA: 26] [Impact Index Per Article: 1.2] [Reference Citation Analysis] [Abstract] [MESH Headings] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 01/09/2002] [Accepted: 07/18/2002] [Indexed: 11/04/2022] Open
Abstract
The serotype distribution of 781 nasopharyngeal pneumococcal isolates recovered from 2448 unselected children aged 2-23 months was studied. Only 3.9% of the children for whom cultures were performed attended day care centers. The proportions of pneumococcal isolates that belonged to serotypes related to the 7-, 9- and 11-valent conjugate pneumococcal vaccine were 65%, 66%, and 70%, respectively. The pneumococcal carriage rate among untreated children was 34%; the rates among children treated with antibiotics during the periods 1-30 or 31-60 days before the time of nasopharyngeal sampling were 25% and 36%, respectively. There was a significant positive association between antimicrobial use and carriage of antibiotic-resistant pneumococci, which belonged mainly to vaccine-related serotypes. The proportion of isolates that belonged to vaccine-related serotypes in untreated carriers was 72%; however, the proportions in carriers treated 1-30 days or 31-60 days before sampling were 66% and 56%, respectively. In the nasopharynx, antimicrobial use selects for antibiotic-resistant pneumococci, mainly of vaccine-related serotypes, whereas it may promote an increase in the frequency of colonization with nonvaccine serotypes.
Collapse
Affiliation(s)
- George A Syrogiannopoulos
- Department of Pediatrics, Division of Infectious Disease, University of Patras, School of Medicine, General University Hospital, Patras, Greece.
| | | | | | | |
Collapse
|
6
|
Coles CL, Rahmathullah L, Kanungo R, Thulasiraj RD, Katz J, Santhosham M, Tielsch JM. Vitamin A supplementation at birth delays pneumococcal colonization in South Indian infants. J Nutr 2001; 131:255-61. [PMID: 11160543 DOI: 10.1093/jn/131.2.255] [Citation(s) in RCA: 30] [Impact Index Per Article: 1.3] [Reference Citation Analysis] [Abstract] [MESH Headings] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/13/2022] Open
Abstract
Nasopharyngeal colonization is a risk factor for pneumococcal disease, a leading cause of complications and death in infants. We assessed the impact of vitamin A supplementation in reducing pneumococcal colonization in infants from an area with endemic vitamin A deficiency. We recruited 464 2-mo-old infants from a rural area in South India. Infants were randomly assigned to receive two 7000-microg retinol equivalent doses of vitamin A (n = 239) or placebo (n = 225) orally at birth, and nasopharyngeal specimens were collected at ages 2, 4 and 6 mo. We studied the effect of vitamin A on culture-confirmed pneumococcal colonization and on the distribution of pneumococcal serotypes. Analyses were conducted by intention-to-treat. The risk of colonization among infants aged 4 mo who were not colonized by age 2 mo was significantly reduced in the vitamin A group compared with the placebo group [odds ratio 0.51 (0.28, 0.92), P = 0.02). The odds of colonization were 27% lower in the treatment group than in the placebo group [odds ratio 0.73 (0.48, 1.1), P = 0.13]. No differences were detected in the prevalence of invasive serotypes. The risk of colonization with penicillin-resistant isolates was 74% lower in the vitamin A group than in the placebo group at 2 mo of age. However, the prevalence of penicillin-resistant isolates was only 4%. Neonatal vitamin A supplementation may play a role in lowering morbidity rates associated with pneumococcal disease by delaying the age at which colonization occurs.
Collapse
Affiliation(s)
- C L Coles
- Department of International Health, John Hopkins School of Hygiene & Public Health, Baltimore 21205, USA
| | | | | | | | | | | | | |
Collapse
|
7
|
Ivarsson M, Quiding-Järbrink M, Lundberg C. Immunoglobulin-secreting cells in the surface secretion on the pharyngeal tonsils. Acta Otolaryngol 2000; 119:939-43. [PMID: 10728938 DOI: 10.1080/00016489950180324] [Citation(s) in RCA: 11] [Impact Index Per Article: 0.5] [Reference Citation Analysis] [Abstract] [MESH Headings] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 10/17/2022]
Abstract
As B-lymphocytes on the pharyngeal tonsils constitute a considerable part of the leukocytes in the surface secretion, and their biological role is obscure, we explored their possible function with respect to immunoglobulin production. Twenty children scheduled for routine adenoidectomy participated. Surface secretion from 10 children was analysed for presence of plasma cells and cells from the secretions of the other 10 children were tested in enzyme-linked immunosorbent spot assays (ELISPOT-assays) for their capacity to secrete and produce IgA, IgM and IgG. Plasma cells and cells that secreted IgA, IgM and IgG respectively were present in the secretions of all tested children. In eight of ten children the IgG immunocytes, Ig-producing blasts and plasma cells. outnumbered the IgA immunocytes. The number of immunoglobulin secreting cells (ISCs) was reduced by half or more in cell suspensions exposed to the reversible protein synthesis inhibitor cycloheximide. It is concluded that immunocytes that produce and secrete immunoglobulin are present in the surface secretion on the pharyngeal tonsils. The production represents an addition to the immunoglobulins transported to the secretion by the poly-Ig receptor and by passive diffusion. The results shed new light on the pathogenesis of mucosal infections in the upper airways.
Collapse
Affiliation(s)
- M Ivarsson
- Department of Otorhinolaryngology, Sahlgrenska University Hospital, Göteborg, Sweden.
| | | | | |
Collapse
|
8
|
Korkeila M, Lehtonen H, Ahman H, Leroy O, Eskola J, Käyhty H. Salivary anti-capsular antibodies in infants and children immunised with Streptococcus pneumoniae capsular polysaccharides conjugated to diphtheria or tetanus toxoid. Vaccine 2000; 18:1218-26. [PMID: 10649623 DOI: 10.1016/s0264-410x(99)00393-x] [Citation(s) in RCA: 37] [Impact Index Per Article: 1.5] [Reference Citation Analysis] [Abstract] [MESH Headings] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/28/2022]
Abstract
Saliva samples of infants and children immunised with pneumococcal vaccines were analysed for anti-polysaccharide (PS) antibodies against the Streptococcus pneumoniae (Pnc) vaccine serotypes 6B, 14, 19F, and 23F. The children received Pnc conjugate vaccine (1, 3, or 10 micrograms of PSs conjugated to diphtheria or tetanus toxoid) or placebo at 2, 4, and 6 months. At 7 months of age salivary PS antibodies were detected rarely. All children received Pnc conjugate or PS vaccine at 14 months of age. At 15 months, both IgA and IgG anti-Pnc PS were found, anti-19F and anti-14 antibodies occurring most frequently and in the highest concentrations. IgA was in the secretory form and predominantly IgA1. A negative dose dependency was observed in IgA anti-19F response. In general, no clear differences in salivary antibody responses were found between the children primed with conjugate vaccine in infancy and those who received their first Pnc vaccine at 14 months of age, suggesting that priming with Pnc conjugate vaccines does not lead to remarkable mucosal memory responses.
Collapse
Affiliation(s)
- M Korkeila
- National Public Health Institute, Helsinki, Finland.
| | | | | | | | | | | |
Collapse
|
9
|
Nieminen T, Käyhty H, Leroy O, Eskola J. Pneumococcal conjugate vaccination in toddlers: mucosal antibody response measured as circulating antibody-secreting cells and as salivary antibodies. Pediatr Infect Dis J 1999; 18:764-72. [PMID: 10493335 DOI: 10.1097/00006454-199909000-00005] [Citation(s) in RCA: 33] [Impact Index Per Article: 1.3] [Reference Citation Analysis] [Abstract] [MESH Headings] [Track Full Text] [Journal Information] [Submit a Manuscript] [Subscribe] [Scholar Register] [Indexed: 11/26/2022]
Abstract
BACKGROUND Our previous studies have shown an antibody-secreting cell (ASC) response to pneumococcal vaccines in adults and suggested that a high IgA ASC response is an indicator of a secretory IgA response in saliva. We believe that the mucosal immune response is potentially an important characteristic of the pneumococcal vaccines and should thus be measured when the new pneumococcal conjugate vaccines are evaluated. OBJECTIVES To study mucosal and serum antibody responses to pneumococcal conjugate vaccines in toddlers. METHODS Each investigational vaccine, containing either 3 or 10 microg of pneumococcal PS serotypes 6B, 14, 19F and 23F conjugated to either diphtheria toxoid (PncD) or tetanus protein (PncT), was administered to 10 children (a total of 40 children). The ASC response was measured on Day 7 after immunization by enzyme-linked immunospot assay, and the salivary and serum antibodies were measured before and 7 and 28 days after the immunization by enzyme immunoassay. RESULTS The vaccines studied induced ASC responses to the pneumococcal polysaccharides (PS) in all children vaccinated. The ASC responses to the PS components of the vaccine (the geometric mean number of ASCs varying from 120 to 160 ASC/10(6) cells) were lower than those seen earlier in adults after conjugate vaccine (240 to 2015 ASC/10(6) cells), but comparable with those seen earlier in adults after pneumococcal PS vaccine (113 to 136 ASC/10(6) cells). The ASC response was clearly dominated by IgA-secreting cells. Salivary IgA responses were detected in 35% of the children, but IgG was rarely detected in saliva. A positive correlation was demonstrated between the number of IgA ASCs and salivary IgA concentration (r = 0.70, P = 0.01), suggesting that a high number of IgA ASCs after parenteral immunization is an indicator of a secretory IgA response in saliva. On Day 28 after immunization increased serum concentrations of IgG were detected in most vaccinees (75 to 95%, depending on the serotype). CONCLUSIONS Both mucosal and systemic antibody responses were induced by PncD and PncT vaccines in toddlers.
Collapse
Affiliation(s)
- T Nieminen
- National Public Health Institute, Helsinki, Finland.
| | | | | | | |
Collapse
|
10
|
Affiliation(s)
- F Ghaffar
- Department of Pediatrics, University of Texas Southwestern Medical Center, Dallas, USA
| | | | | |
Collapse
|
11
|
Takada R, Harabuchi Y, Himi T, Kataura A. Antibodies specific to outer membrane antigens of Moraxella catarrhalis in sera and middle ear effusions from children with otitis media with effusion. Int J Pediatr Otorhinolaryngol 1998; 46:185-95. [PMID: 10190589 DOI: 10.1016/s0165-5876(98)00158-x] [Citation(s) in RCA: 10] [Impact Index Per Article: 0.4] [Reference Citation Analysis] [Abstract] [MESH Headings] [Track Full Text] [Journal Information] [Submit a Manuscript] [Subscribe] [Scholar Register] [Indexed: 10/17/2022]
Abstract
OBJECTIVE Recent studies have shown that bacterial DNA is present in a significant percentage of middle ear effusions, suggesting that persistent bacterial infection may be more important in pathogenesis and recurrence of otitis media with effusion (OME) than previously considered. Although Moraxella (M.) catarrhalis is one of the most common pathogens of otitis media, relatively little is known about immune response to the organism. The objective of the present study is to investigate how systemic and local immune activities against M. catarrhalis may be associated with severity of OME. METHODS The antibody levels specific to outer membrane antigens of M. catarrhalis in sera and middle ear effusions (MEEs) from 59 children with OME were measured by enzyme-linked immunosorbent assay. Their ages ranged from 1 to 12 years with a median 5.0 years. The children were followed 1 year prospectively and classified into two groups with or without recurrent/persistent OME according to severity of OME during the follow-up 1 year. RESULTS Serum IgG, IgM, and IgA antibodies specific to outer membrane antigens of M. catarrhalis were detected in all samples and the median levels were 35, 0.93, and 1.2 microg/ml respectively. The MEE IgG, IgM, IgA, and secretory IgA antibodies were detected in over 95% samples tested and the median levels were 371, 158, 20, and 50 ng/mg total protein respectively. A comparison between acute and subacute/chronic phases revealed that the median levels of MEE IgG and IgM antibodies were higher at the acute phase (692 vs. 340, P = 0.06; 35 vs. 10, P = 0.02, respectively); while the MEE secretory IgA antibody level was increased at the subacute/chronic phase (74 vs. 35, P = 0.02). Either serum or MEE IgG antibody level was significantly lower in recurrent/persistent OME group than that in nonrecurrent/non-persistent OME group (13 vs. 43 ,microg/ml, P = 0.009; 238 vs. 577 ng/mg protein, P = 0.006, respectively). CONCLUSIONS These data provide additional information on the immunologic aspects of children with OME. Decreased serum and MEE IgG antibody levels specific to outer membrane antigens of M. catarrhalis may lead to failure to eliminate this organism, resulting in persistent and/or recurrent appearance of MEE.
Collapse
Affiliation(s)
- R Takada
- Department of Otolaryngology, Sapporo Medical University School of Medicine, Japan
| | | | | | | |
Collapse
|
12
|
Miravitlles M, de Gracia J. [Antipneumococcal vaccines. Old controversies and new indications (II)]. Arch Bronconeumol 1998; 34:353-7. [PMID: 9762397 DOI: 10.1016/s0300-2896(15)30403-8] [Citation(s) in RCA: 2] [Impact Index Per Article: 0.1] [Reference Citation Analysis] [MESH Headings] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 02/09/2023]
Affiliation(s)
- M Miravitlles
- Servicio de Neumología, Hospital General Universitario Vall d'Hebron, Barcelona.
| | | |
Collapse
|
13
|
Miravitlles M, de Gracia J. [Antipneumococcal vaccine. Old controversies and new indications]. Arch Bronconeumol 1998; 34:295-9. [PMID: 9666288 DOI: 10.1016/s0300-2896(15)30416-6] [Citation(s) in RCA: 3] [Impact Index Per Article: 0.1] [Reference Citation Analysis] [MESH Headings] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/17/2022]
Affiliation(s)
- M Miravitlles
- Servicio de Neumología, Hospital General Universitario Vall d'Hebron, Barcelona.
| | | |
Collapse
|
14
|
Nieminen T, Eskola J, Käyhty H. Pneumococcal conjugate vaccination in adults: circulating antibody secreting cell response and humoral antibody responses in saliva and in serum. Vaccine 1998; 16:630-6. [PMID: 9569475 DOI: 10.1016/s0264-410x(97)00235-1] [Citation(s) in RCA: 34] [Impact Index Per Article: 1.3] [Reference Citation Analysis] [Abstract] [MESH Headings] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 02/07/2023]
Abstract
The results from our previous study showed IgA dominated ASC responses to pneumococcal polysaccharide vaccine and to pneumococcal polysaccharide meningococcal outer membrane protein conjugate vaccine (PncOMPC) in adult volunteers. The results indicated that a high IgA ASC response is a useful indicator of a secretory IgA response in saliva. We believe that the mucosal immune responses is potentially an important characteristic of the pneumococcal vaccines and should thus be measured when the new pneumococcal conjugate vaccines are evaluated. In the present study, we studied two new tetravalent pneumococcal conjugate vaccines: the diphtheria toxoid and tetanus toxoid conjugates. In contrast to PncOMPC, these conjugates induced higher responses than the polysaccharide vaccine. Furthermore, the different structure of the two conjugate vaccines might affect the nature of the response. Thus a different vaccine may be optimal for induction of a mucosal response than is of systemic responses.
Collapse
Affiliation(s)
- T Nieminen
- National Public Health Institute, Helsinki, Finland.
| | | | | |
Collapse
|
15
|
Nieminen T, Käyhty H, Virolainen A, Eskola J. Circulating antibody secreting cell response to parenteral pneumococcal vaccines as an indicator of a salivary IgA antibody response. Vaccine 1998; 16:313-9. [PMID: 9607048 DOI: 10.1016/s0264-410x(97)00162-x] [Citation(s) in RCA: 36] [Impact Index Per Article: 1.4] [Reference Citation Analysis] [Abstract] [MESH Headings] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 02/07/2023]
Abstract
This study assessed the mucosal immune response in healthy adult volunteers immunized parenterally with either pneumococcal polysaccharide (N = 8) or pneumococcal polysaccharide-protein conjugate (N = 10) vaccine with an aim to evaluate the relevance of antibody secreting cell (ASC) response after parenteral vaccination. An ASC response to the four types of capsular polysaccharide tested was observed in all vaccinees 7-9 days after immunization. IgA was the predominant class in the ASC response, and IgG the next common, with very few IgM ASCs. The IgA/IgG ratio in the ASC response was higher after immunization with the polysaccharide than the conjugate vaccine. Antibodies of the IgA class were frequently seen in the saliva already before immunization; especially to serotypes 14 and 19F. A twofold increase of the type specific secretory IgA antibodies in saliva was found in eight of the 16 instances in which the specific IgA ASC response was > 100 ASC per 10(6) cells and in only one of the 52 instances with fewer ASCs. We conclude that the ASC response in the peripheral blood is a useful parameter of the antibody response to pneumococcal vaccines and a good indicator of a secretory IgA response in the saliva.
Collapse
Affiliation(s)
- T Nieminen
- National Public Health Institute, Helsinki, Finland
| | | | | | | |
Collapse
|